Welcome to our dedicated page for HeartBeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC as sales agent. Under this agreement, HeartBeam may sell from time to time up to $25,000,000 of common stock through at-the-market offerings under its existing shelf Registration Statement on Form S-3. The company filed a prospectus supplement dated August 14, 2026 covering these sales. Titan Partners will receive a commission of up to 3% of the gross sales price per share and has been provided customary indemnification and contribution rights.
HeartBeam, Inc. is launching an “at‑the‑market” equity program to sell up to $25,000,000 of common stock from time to time through Titan Partners Securities as sales agent. Titan will receive a cash commission of 3.0% of gross proceeds and may be deemed an underwriter.
The company’s common stock trades on Nasdaq under “BEAT”; the last reported price on August 13, 2026 was $0.5898 per share, implying up to about 42.4 million shares if fully utilized at that price, compared with 56,349,171 shares outstanding before this offering. Net proceeds are intended for working capital and general corporate purposes, with management retaining broad discretion over deployment.
HeartBeam is a pre‑revenue medical technology company focused on ambulatory, cable‑free, synthesized 12‑lead ECG solutions, supported by a growing international patent portfolio and recent FDA clearances. Independent auditors’ reports for 2024 and 2025 included explanatory paragraphs raising substantial doubt about the company’s ability to continue as a going concern, and the filing highlights dilution and share‑price pressure risks from this ATM program.
HeartBeam, Inc. (BEAT) has an amended Schedule 13D filing from Mark E. Strome and affiliated entities regarding holdings of its common stock. Strome Mezzanine Fund II, LP purchased 750,000 shares in HeartBeam’s underwritten public offering of 12,500,000 shares at $0.80 per share, for a total of $600,000, funded with its own capital.
Following this and other positions, Mark E. Strome reports beneficial ownership of 3,764,200 shares, or 6.8% of HeartBeam’s common stock, based on 55,506,835 shares outstanding as of May 11, 2026. Strome Group, Inc., Strome Investment Management, LP and Strome Mezzanine Fund II, LP each report 3,650,000 shares, or 6.6%, with shared voting and dispositive power. The filing lists numerous recent open-market sales by the Fund between July 6 and August 12, 2026 at prices generally between $0.49 and $0.69 per share, which are noted as not yet reflected in the reported aggregate ownership figures.
HeartBeam, Inc. reported no revenue for the quarter and six months ended June 30, 2026 and continues to operate at a loss while developing its ambulatory cardiac monitoring platform. Net loss was $5.0 million for the quarter and $9.7 million for the first half of 2026.
Cash and cash equivalents were $8.7 million as of June 30, 2026, up from $4.4 million at year-end, primarily from an underwritten equity offering that generated $11.5 million in gross proceeds (about $10.3 million net) plus at-the-market sales. Operating cash outflow was $7.0 million in the first half.
The company discloses that existing liquidity is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. It received FDA clearances in December 2024 and December 2025 for its 3D ECG telehealth products, is running pilot and ALIGN-ACS studies, and is pursuing a shift toward licensing its 3D ECG signal technology and limited commercial launches. During the quarter HeartBeam also recorded CEO and director departures and received a Nasdaq minimum bid-price deficiency notice with a compliance period through December 29, 2026.
HeartBeam, Inc. filed an amendment to update terms related to the departure of Robert P. Eno, confirming that a Separation Agreement and an Advisory Agreement were executed on July 30, 2026.
Under the Separation Agreement, Mr. Eno receives a lump sum cash payment of $300,000, equal to nine months of base salary, in exchange for a release of claims and continued compliance with restrictive covenants. He is eligible to serve as a non-employee advisor under the Advisory Agreement, with a one-time $1,000 advisory retainer. All of his outstanding stock options and restricted stock units fully vest, and the post-termination exercise period for each option is extended until the earlier of December 31, 2027 or the option’s original expiration. HeartBeam will also reimburse up to nine months of COBRA premiums.
HeartBeam, Inc. reported the results of its July 31, 2026 annual stockholder meeting held via live webcast. As of the June 5, 2026 record date, 55,506,835 shares of common stock were outstanding and entitled to vote, and 29,050,272 votes, or 52.34% of outstanding votes, were represented, constituting a quorum.
Stockholders elected all seven director nominees to one-year terms, with each receiving over 10 million votes in favor and approximately 0.9–1.3 million votes against, plus broker non-votes. They also approved the ratification of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 28,612,850 votes for and 173,008 against.
A proposal to amend the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000 shares did not receive stockholder approval, drawing 3,957,529 votes for, 7,816,794 against, 41,929 abstentions and 17,234,020 broker non-votes.
HeartBeam, Inc. reported that Chief Technology Officer Kenneth Harry Persen acquired 105,740 shares of common stock on July 24, 2026 through a grant treated as Restricted Stock Units under the 2022 Equity Incentive Plan.
The RSUs vested in full on the grant date as part of the 2025 Bonus Program, with executives receiving shares in lieu of cash. Following this award, Persen directly holds 448,290 shares of HeartBeam common stock.
Cruickshank Tim reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported that CFO Tim Cruickshank received a grant of 167,760 shares of common stock in the form of Restricted Stock Units on July 24, 2026 under the 2022 Equity Incentive Plan. The RSUs vested in full on the grant date as shares-in-lieu-of-cash for the 2025 Bonus Program, increasing his directly held shares to 239,990.
Vajdic Branislav reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported equity awards to President and director Branislav Vajdic under its 2022 Equity Incentive Plan. On June 15, 2026 he was granted 2,800,000 performance-based PRSUs that vest over three years upon achievement of milestones and continued service. On July 24, 2026 he received 260,870 RSUs, which vested in full on the grant date and settled his 2025 bonus in shares instead of cash.
HeartBeam, Inc. has received a Nasdaq notice that its common stock is out of compliance with the exchange’s $1.00 minimum bid price requirement, after trading below this level for 30 consecutive business days.
The company has 180 calendar days, until December 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if other Nasdaq listing standards, including market value of publicly held shares, are met.
The notice does not immediately affect HeartBeam’s Nasdaq Capital Market listing, but failure to regain compliance could ultimately lead to delisting, subject to possible appeal to a Nasdaq hearings panel.